Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 1
2009 3
2013 1
2015 1
2017 1
2018 3
2019 2
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer.
Chitty JL, Yam M, Perryman L, Parker AL, Skhinas JN, Setargew YFI, Mok ETY, Tran E, Grant RD, Latham SL, Pereira BA, Ritchie SC, Murphy KJ, Trpceski M, Findlay AD, Melenec P, Filipe EC, Nadalini A, Velayuthar S, Major G, Wyllie K, Papanicolaou M, Ratnaseelan S, Phillips PA, Sharbeen G, Youkhana J, Russo A, Blackwell A, Hastings JF, Lucas MC, Chambers CR, Reed DA, Stoehr J, Vennin C, Pidsley R, Zaratzian A, Da Silva AM, Tayao M, Charlton B, Herrmann D, Nobis M, Clark SJ, Biankin AV, Johns AL, Croucher DR, Nagrial A, Gill AJ, Grimmond SM; Australian Pancreatic Cancer Genome Initiative (APGI); Australian Pancreatic Cancer Matrix Atlas (APMA); Pajic M, Timpson P, Jarolimek W, Cox TR. Chitty JL, et al. Among authors: findlay ad. Nat Cancer. 2023 Sep;4(9):1326-1344. doi: 10.1038/s43018-023-00614-y. Epub 2023 Aug 28. Nat Cancer. 2023. PMID: 37640930 Free PMC article.
Topical application of an irreversible small molecule inhibitor of lysyl oxidases ameliorates skin scarring and fibrosis.
Chaudhari N, Findlay AD, Stevenson AW, Clemons TD, Yao Y, Joshi A, Sayyar S, Wallace G, Rea S, Toshniwal P, Deng Z, Melton PE, Hortin N, Iyer KS, Jarolimek W, Wood FM, Fear MW. Chaudhari N, et al. Among authors: findlay ad. Nat Commun. 2022 Sep 22;13(1):5555. doi: 10.1038/s41467-022-33148-5. Nat Commun. 2022. PMID: 36138009 Free PMC article.
Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer.
Chang J, Lucas MC, Leonte LE, Garcia-Montolio M, Singh LB, Findlay AD, Deodhar M, Foot JS, Jarolimek W, Timpson P, Erler JT, Cox TR. Chang J, et al. Among authors: findlay ad. Oncotarget. 2017 Apr 18;8(16):26066-26078. doi: 10.18632/oncotarget.15257. Oncotarget. 2017. PMID: 28199967 Free PMC article.
Author Correction: Topical application of an irreversible small molecule inhibitor of lysyl oxidases ameliorates skin scarring and fibrosis.
Chaudhari N, Findlay AD, Stevenson AW, Clemons TD, Yao Y, Joshi A, Sayyar S, Wallace G, Rea S, Toshniwal P, Deng Z, Melton PE, Hortin N, Iyer KS, Jarolimek W, Wood FM, Fear MW. Chaudhari N, et al. Among authors: findlay ad. Nat Commun. 2023 Jan 10;14(1):135. doi: 10.1038/s41467-023-35849-x. Nat Commun. 2023. PMID: 36627321 Free PMC article. No abstract available.
17 results